The new World Health Organization classification of lymphomas: The past, the present and the future

Hematological Oncology

Volumn 19, Issue 4, 2001, Pages 129-150

  Chan, John K C ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Classification; Hodgkin's lymphoma; Immunohistochemistry; Lymphoma; Molecular genetics; REAL classification; WHO classification

Indexed keywords

PROTEIN BCL 2; PROTEIN BCL 6;

B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CLINICAL FEATURE; DNA MICROARRAY; HISTIOCYTIC LYMPHOMA; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; MAST CELL LEUKEMIA; MEDICAL SOCIETY; MOLECULAR GENETICS; MYELOID LEUKEMIA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; REVIEW; SYMPTOM; T CELL LYMPHOMA; WORLD HEALTH ORGANIZATION;

FORECASTING; HUMANS; LYMPHOMA; WORLD HEALTH ORGANIZATION;

EID: 0035688916     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.660     Document Type: Review

References (76)

1. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project
2. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
3. Evaluation of the Revised European-American Lymphoma. Classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma
4. Peripheral T-cell lymphomas: An evaluation of reproducibility of the updated Kiel classification
5. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
6. A revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version
7. A proposal for classification of lymphoid neoplasms (by the International Lymphoma Study Group)
8. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: A comparison with the Working Formulation
9. A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group study
10. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project
11. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types
12. Is the REAL classification for real? Do we need a separate classification for cutaneous lymphomas?
13. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades
14. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial
15. Is the International Prognostic Index for Aggressive Lymphoma patients useful for follicular lymphoma patients?
16. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma
17. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997
18. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997
19. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997
20. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997
21. World Health Organization Classification of lymphomas: A work in progress
22. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report
23. The current status of lymphoma classification
24. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription
25. Cellular origin of human B-cell lymphomas
26. Hodgkin's disease: Biology and origin of Hodgkin and Reed-Sternberg cells
27. Cellular origin and clonality of classic Hodgkin's lymphoma: Immunophenotypic and molecular studies
28. The nature of Reed-Sternberg cells, lymphocytic and histiocytic cells and their molecular biology in Hodgkin's disease
29. Somatic mutations within the untranslated regions of rearranged Ig genes in a case of classical Hodgkin's disease as a potential cause for the absence of Ig in the lymphoma cells
30. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells
31. Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group
32. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease
33. Clinical presentation and treatment of lymphocyte predominance Hodgkin's disease
34. European task force on lymphoma project on lymphocyte predominance Hodgkin disease: Histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes
35. Non-MALT marginal zone B-cell lymphomas: A description of clinical presentation and outcome in 124 patients
36. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas
37. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation
38. The t(11;18)(q21;q21) is the most common translocation in MALT lymphomas
39. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas
40. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type
41. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue
42. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18
43. API2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products
44. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
45. Anaplastic large cell lymphoma: A clinicopathologic analysis
46. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity
47. Anaplastic large cell lymphoma: A distinct molecular pathologic entity: A reappraisal with special reference to p80(NPM/ALK) expression
48. ALK + lymphoma: Clinico-pathological findings and outcome
49. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK
50. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: A clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma
51. The perivascular cuff of large lymphoid cells: A clue to diagnosis of anaplastic large cell lymphoma
52. Mediastinal large B-cell lymphoma: New evidence in support of its distinctive identity
53. The MAL gene is expressed in primary mediastinal large B-cell lymphoma
54. Tumors of the lymphoreticular system, including spleen and thymus
55. Natural killer cell neoplasms
56. Peripheral T-cell and NK-cell neoplasms: An integrated approach to diagnosis
57. ALK-positive lymphoma: A single disease with a broad spectrum of morphology
58. Primary and secondary cutaneous CD30+ lymphoproliferative disorders: A report from the Dutch cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment
59. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis
60. Proliferation and cellular phenotype in lymphomatoid granulomatosis: Implications of a higher proliferation index in B cells
61. Lymphomatoid granulomatosis: Evidence that some cases represent Epstein-Barr virus-associated B-cell lymphoma
62. Lymphomatoid granulomatosis. Evidence of immunophenotypic diversity and relationship to Epstein-Barr virus infection
63. Lymphomatoid granulomatosis: Pathogenesis, pathology and clinical implications
64. AIDS-related plasmablastic lymphomas of the oral cavity and jaws: A diagnostic dilemma
65. Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection
66. Criteria for the cytologic subclassification of follicular lymphomas: A proposed alternative method
67. Lymphoma classification-the gap between biology and clinical management is closing
68. Natural history of and therapy for the indolent non-Hodgkin's lymphomas
69. Making and using DNA microarrays: A short course at Cold Spring Harbor Laboratory
70. How DNA microarrays and expression profiling will affect clinical practice
71. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
72. Examining the living genome in health and disease with DNA microarrays
73. Exploring the new world of the genome with DNA microarrays
74. Expression profiling using cDNA microarrays
75. Mutational analysis using oligonucleotide microarrays